Milestone Pharmaceuticals (NASDAQ:MIST) and Harrow (NASDAQ:HROW) Financial Survey

Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) and Harrow (NASDAQ:HROW – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Institutional & Insider Ownership

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by company insiders. Comparatively, 12.8% of Harrow shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Milestone Pharmaceuticals and Harrow’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Milestone Pharmaceuticals N/A -288.33% -58.27%
Harrow -9.39% -69.81% -5.16%

Risk & Volatility

Milestone Pharmaceuticals has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Harrow has a beta of 0.18, suggesting that its share price is 82% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Milestone Pharmaceuticals and Harrow, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Milestone Pharmaceuticals 1 1 5 1 2.75
Harrow 2 1 6 0 2.44

Milestone Pharmaceuticals presently has a consensus target price of $5.83, indicating a potential upside of 1,498.17%. Harrow has a consensus target price of $66.20, indicating a potential upside of 127.57%. Given Milestone Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts plainly believe Milestone Pharmaceuticals is more favorable than Harrow.

Earnings & Valuation

This table compares Milestone Pharmaceuticals and Harrow”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Milestone Pharmaceuticals $1.55 million 29.32 -$63.06 million ($0.75) -0.49
Harrow $272.30 million 4.01 -$5.14 million ($0.78) -37.29

Harrow has higher revenue and earnings than Milestone Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Milestone Pharmaceuticals beats Harrow on 8 of the 14 factors compared between the two stocks.

About Milestone Pharmaceuticals

(Get Free Report)

Milestone Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cardiovascular conditions. Its work centers on therapies intended to give patients and caregivers options for managing acute heart rhythm episodes outside of a clinical setting. The company’s lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. It is designed for self-administration to treat episodes of paroxysmal supraventricular tachycardia, a condition involving sudden episodes of abnormally fast heart rate.

About Harrow

(Get Free Report)

Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.

Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.